Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    Rabin Medical Center
Updated on 7 November 2020
tacrolimus
immunosuppressive agents
renal impairment
kidney biopsy

Summary

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose. The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance. The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.

Description

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose. The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance. The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range. Patients will undergo the following baseline studies: 1. Doppler ultrasound to exclude any mechanical or a vascular problem. 2. A kidney biopsy to define the histological changes (degree of interstitial fibrosis, tubular and glomerular changes). The biopsies will be stained also for C4D and for fibrinogenic markers (TGF-beta, and collagen). 3. A 24-hour urine protein excretion and creatinine clearance 4. Echocardiography study 5. Carotid Ultrasound The following parameters will be monitored every clinic visit throughout the study period: 1. SMA-12 including creatinine levels. 2. A complete blood count. 3. Cholesterol, HDL-cholesterol and triglyceride levels. 4. Blood pressure measurements (X2) 5. The number of blood pressure medications. 6. Cholesterol lowering medication requirement 7. Urine protein excretion (quantitative spot-test ) 8. Protein amount in the urine Study end points: The data will be evaluated based on an intention to treat analysis and the following parameters will be compared between the two groups: 1. Creatinine levels and calculated creatinine clearance 2. Spot urine for Cr./protein ratio 3. 24-hr. protein excretion 4. Change in peak diastolic and mean arterial blood pressure 5. The number and dosage of blood pressure medications 6. Cholesterol, HDL and triglyceride levels 7. Proportion of patients on cholesterol lowering agents 8. Number and severity of biopsy proven acute rejection episodes 9. Incidence of biopsy proven chronic rejection. (depends on per protocol biopsy at end of study) 10. Patient and graft survival

Details
Condition Nephropathy
Treatment adding Certican to therapy, reducing Tacrolimus
Clinical Study IdentifierNCT00443508
SponsorRabin Medical Center
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note